glp 1 china China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart from other GLP‑1 drugs. What makes China has approved Pfizer's GLP-1
Pay in 4 interest-free payments of $5.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14

















30313-2/asset/a19d0b94-6294-44c8-a664-8b778d88133e/main.assets/gr3_lrg.jpg)




